| answer text |
<p>The National Institute for Health and Care Excellence (NICE) is the independent
body responsible for developing evidence-based guidance for the National Health Service
on whether new medicines represent a clinically and cost-effective use of resources.
NICE’s guidance is based on a thorough assessment of the available evidence and developed
through extensive engagement with stakeholders. NICE was unable to recommend bevacizumab
(Avastin) as an effective use of NHS resources for the treatment of metastatic colorectal
cancer, and it is not routinely funded on the NHS in England.</p><p> </p><p>NICE has
been asked to consider updating its appraisals of bevacizumab for colorectal cancer
given that there are now multiple biosimilars available, some at significantly lower
cost than the price at which bevacizumab was originally assessed. However, NICE must
also take into consideration wider considerations regarding the use of bevacizumab
in different scenarios that have evolved since the original appraisals. NICE is exploring
options and further information on any proposed changes will be made available in
due course.</p>
|
|
